Veracyte (VCYT) Expected to Announce Quarterly Earnings on Wednesday

Key Points

• Veracyte (NASDAQ:VCYT) is set to announce its Q2 2025 earnings on August 6, with analysts expecting earnings of $0.31 per share and revenue of $120.90 million.
• The company’s shares opened at $24.47, reflecting a 1-year low of $19.73 and a high of $47.32, while its market capitalization stands at $1.92 billion.
• Recent reports show analysts have mixed views on the stock, with the price targets from various brokerages ranging from $37.00 to $42.00 and an overall average rating of "Moderate Buy".

Veracyte (NASDAQ:VCYT - Get Free Report) is expected to be announcing its Q2 2025 earnings results after the market closes on Wednesday, August 6th. Analysts expect the company to announce earnings of $0.31 per share and revenue of $120.90 million for the quarter.

Veracyte Stock Performance

Shares of NASDAQ VCYT traded up $0.13 during trading on Friday, reaching $23.64. The company had a trading volume of 1,741,593 shares, compared to its average volume of 1,967,193. Veracyte has a 52 week low of $19.73 and a 52 week high of $47.32. The business's 50 day moving average price is $26.23 and its 200-day moving average price is $31.61. The stock has a market cap of $1.85 billion, a PE ratio of 57.66 and a beta of 1.97.

Analysts Set New Price Targets

Several brokerages have recently commented on VCYT. Needham & Company LLC lowered their price target on shares of Veracyte from $51.00 to $41.00 and set a "buy" rating for the company in a research report on Thursday, May 8th. UBS Group lowered their price target on shares of Veracyte from $49.00 to $42.00 and set a "buy" rating for the company in a research report on Thursday, May 8th. Wall Street Zen upgraded shares of Veracyte from a "hold" rating to a "buy" rating in a research report on Saturday, July 26th. Finally, Guggenheim decreased their price objective on shares of Veracyte from $45.00 to $37.00 and set a "buy" rating for the company in a report on Wednesday, April 9th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and nine have issued a buy rating to the company's stock. According to MarketBeat.com, Veracyte has an average rating of "Moderate Buy" and an average target price of $40.90.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of VCYT. Jane Street Group LLC lifted its stake in Veracyte by 94.7% in the first quarter. Jane Street Group LLC now owns 216,909 shares of the biotechnology company's stock valued at $6,431,000 after buying an additional 105,499 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in shares of Veracyte by 12.2% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 195,793 shares of the biotechnology company's stock worth $5,805,000 after purchasing an additional 21,330 shares in the last quarter. Intech Investment Management LLC lifted its position in shares of Veracyte by 54.1% in the first quarter. Intech Investment Management LLC now owns 42,762 shares of the biotechnology company's stock worth $1,268,000 after purchasing an additional 15,017 shares in the last quarter. Finally, Royal Bank of Canada lifted its position in shares of Veracyte by 23.3% in the first quarter. Royal Bank of Canada now owns 28,712 shares of the biotechnology company's stock worth $852,000 after purchasing an additional 5,435 shares in the last quarter.

About Veracyte

Veracyte, Inc engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H.